schliessen

Filtern

 

Bibliotheken

Automated radiofrequency-based US measurement of common carotid intima–media thickness in RA patients treated with synthetic synthetic and biologic DMARDs

Objective. To compare the carotid intima–media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls. Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centr... Full description

Journal Title: Rheumatology 2013, Vol. 52(2), pp.376-381
Main Author: Naredo, Esperanza
Other Authors: Möller, Ingrid , Corrales, Alfonso , Bong, David A , Cobo - Ibáñez, Tatiana , Corominas, Hector , Garcia - Vivar, Ma Luz , Macarrón, Pilar , Navio, Teresa , Richi, Patricia , Iagnocco, Annamaria , Garrido, Jesús , Martínez - Hernández, David
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1462-0324 ; E-ISSN: 1462-0332 ; DOI: 10.1093/rheumatology/kes260
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: oxford10.1093/rheumatology/kes260
title: Automated radiofrequency-based US measurement of common carotid intima–media thickness in RA patients treated with synthetic synthetic and biologic DMARDs
format: Article
creator:
  • Naredo, Esperanza
  • Möller, Ingrid
  • Corrales, Alfonso
  • Bong, David A
  • Cobo - Ibáñez, Tatiana
  • Corominas, Hector
  • Garcia - Vivar, Ma Luz
  • Macarrón, Pilar
  • Navio, Teresa
  • Richi, Patricia
  • Iagnocco, Annamaria
  • Garrido, Jesús
  • Martínez - Hernández, David
subjects:
  • Ultrasound
  • Carotid Intima–Media Thickness
  • Rheumatoid Arthritis
  • Radiofrequency
ispartof: Rheumatology, 2013, Vol. 52(2), pp.376-381
description: Objective. To compare the carotid intima–media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls. Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were recorded. Common carotid artery (CCA)-IMT was assessed in RA patients and controls with automated radiofrequency-based US by the same investigator at each centre. Forty-five (47.9%) RA patients had been treated with synthetic DMARDs and 49 (52.1%) with synthetic and biologic DMARDs. There were no significant differences between the RA patients and controls in demographics, CV co-morbidities and CV disease. There were significantly more smokers among RA patients treated with synthetic and biologic DMARDs ( = 0.036). Disease duration and duration of CS and synthetic DMARD therapy was significantly longer in RA patients treated with synthetic and biologic DMARDs ( < 0.0005). The mean CCA-IMT was significantly greater in RA patients treated only with synthetic DMARDs than in controls [591.4 (98.6) 562.1 (85.8); = 0.035] and in RA patients treated with synthetic and biologic DMARDs [591.4 (98.6) 558.8 (95.3); = 0.040). There was no significant difference between the mean CCA-IMT in RA patients treated with synthetic and biologic DMARDs and controls ( = 0.997). Our results suggest that radiofrequency-based measurement of CCA-IMT can discriminate between RA patients treated with synthetic DMARDs RA patients treated with synthetic and biologic DMARDs.
language:
source:
identifier: ISSN: 1462-0324 ; E-ISSN: 1462-0332 ; DOI: 10.1093/rheumatology/kes260
fulltext: fulltext
issn:
  • 1462-0324
  • 14620324
  • 1462-0332
  • 14620332
url: Link


@attributes
ID1255888081
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1093/rheumatology/kes260
sourceidoxford
recordidTN_oxford10.1093/rheumatology/kes260
sourceformatXML
sourcesystemPC
pqid1273787984
display
typearticle
titleAutomated radiofrequency-based US measurement of common carotid intima–media thickness in RA patients treated with synthetic synthetic and biologic DMARDs
creatorNaredo, Esperanza ; Möller, Ingrid ; Corrales, Alfonso ; Bong, David A ; Cobo - Ibáñez, Tatiana ; Corominas, Hector ; Garcia - Vivar, Ma Luz ; Macarrón, Pilar ; Navio, Teresa ; Richi, Patricia ; Iagnocco, Annamaria ; Garrido, Jesús ; Martínez - Hernández, David
ispartofRheumatology, 2013, Vol. 52(2), pp.376-381
identifier
subjectUltrasound ; Carotid Intima–Media Thickness ; Rheumatoid Arthritis ; Radiofrequency
descriptionObjective. To compare the carotid intima–media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls. Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were recorded. Common carotid artery (CCA)-IMT was assessed in RA patients and controls with automated radiofrequency-based US by the same investigator at each centre. Forty-five (47.9%) RA patients had been treated with synthetic DMARDs and 49 (52.1%) with synthetic and biologic DMARDs. There were no significant differences between the RA patients and controls in demographics, CV co-morbidities and CV disease. There were significantly more smokers among RA patients treated with synthetic and biologic DMARDs ( = 0.036). Disease duration and duration of CS and synthetic DMARD therapy was significantly longer in RA patients treated with synthetic and biologic DMARDs ( < 0.0005). The mean CCA-IMT was significantly greater in RA patients treated only with synthetic DMARDs than in controls [591.4 (98.6) 562.1 (85.8); = 0.035] and in RA patients treated with synthetic and biologic DMARDs [591.4 (98.6) 558.8 (95.3); = 0.040). There was no significant difference between the mean CCA-IMT in RA patients treated with synthetic and biologic DMARDs and controls ( = 0.997). Our results suggest that radiofrequency-based measurement of CCA-IMT can discriminate between RA patients treated with synthetic DMARDs RA patients treated with synthetic and biologic DMARDs.
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Naredo, Esperanza
1Möller, Ingrid
2Corrales, Alfonso
3Bong, David A
4Cobo-Ibáñez, Tatiana
5Corominas, Hector
6Garcia-Vivar, Ma Luz
7Macarrón, Pilar
8Navio, Teresa
9Richi, Patricia
10Iagnocco, Annamaria
11Garrido, Jesús
12Martínez-Hernández, David
titleAutomated radiofrequency-based US measurement of common carotid intima–media thickness in RA patients treated with synthetic synthetic and biologic DMARDs
description
0Objective. To compare the carotid intima–media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls.
1Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were recorded. Common carotid artery (CCA)-IMT was assessed in RA patients and controls with automated radiofrequency-based US by the same investigator at each centre.
2Forty-five (47.9%) RA patients had been treated with synthetic DMARDs and 49 (52.1%) with synthetic and biologic DMARDs. There were no significant differences between the RA patients and controls in demographics, CV co-morbidities and CV disease. There were significantly more smokers among RA patients treated with synthetic and biologic DMARDs ( = 0.036). Disease duration and duration of CS and synthetic DMARD therapy was significantly longer in RA patients treated with synthetic and biologic DMARDs ( < 0.0005). The mean CCA-IMT was significantly greater in RA patients treated only with synthetic DMARDs than in controls [591.4 (98.6) 562.1 (85.8); = 0.035] and in RA patients treated with synthetic and biologic DMARDs [591.4 (98.6) 558.8 (95.3); = 0.040). There was no significant difference between the mean CCA-IMT in RA patients treated with synthetic and biologic DMARDs and controls ( = 0.997).
3Our results suggest that radiofrequency-based measurement of CCA-IMT can discriminate between RA patients treated with synthetic DMARDs RA patients treated with synthetic and biologic DMARDs.
subject
0ultrasound
1carotid intima–media thickness
2rheumatoid arthritis
3radiofrequency
general
0kes260
110.1093/rheumatology/kes260
2Oxford Journals
sourceidoxford
recordidoxford10.1093/rheumatology/kes260
issn
01462-0324
114620324
21462-0332
314620332
rsrctypearticle
creationdate2013
addtitleRheumatology
searchscopeoxford
scopeoxford
lsr40201302
lsr4120121012
lsr30VSR-Enriched:[pqid]
sort
titleAutomated radiofrequency-based US measurement of common carotid intima–media thickness in RA patients treated with synthetic synthetic and biologic DMARDs
authorNaredo, Esperanza ; Möller, Ingrid ; Corrales, Alfonso ; Bong, David A ; Cobo - Ibáñez, Tatiana ; Corominas, Hector ; Garcia - Vivar, Ma Luz ; Macarrón, Pilar ; Navio, Teresa ; Richi, Patricia ; Iagnocco, Annamaria ; Garrido, Jesús ; Martínez - Hernández, David
creationdate20130200
facets
frbrgroupid8926009889463094635
frbrtype5
creationdate2013
topic
0Ultrasound
1Carotid Intima–Media Thickness
2Rheumatoid Arthritis
3Radiofrequency
collectionOxford Journals (Oxford University Press)
prefilterarticles
rsrctypearticles
creatorcontrib
0Naredo, Esperanza
1Möller, Ingrid
2Corrales, Alfonso
3Bong, David A
4Cobo - Ibáñez, Tatiana
5Corominas, Hector
6Garcia - Vivar, Ma Luz
7Macarrón, Pilar
8Navio, Teresa
9Richi, Patricia
10Iagnocco, Annamaria
11Garrido, Jesús
12Martínez - Hernández, David
jtitleRheumatology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Naredo
1Möller
2Corrales
3Bong
4Cobo-Ibáñez
5Corominas
6Garcia-Vivar
7Macarrón
8Navio
9Richi
10Iagnocco
11Garrido
12Martínez-Hernández
aufirst
0Esperanza
1Ingrid
2Alfonso
3David A.
4Tatiana
5Hector
6Ma Luz
7Pilar
8Teresa
9Patricia
10Annamaria
11Jesús
12David
au
0Naredo, Esperanza
1Möller, Ingrid
2Corrales, Alfonso
3Bong, David A.
4Cobo-Ibáñez, Tatiana
5Corominas, Hector
6Garcia-Vivar, Ma Luz
7Macarrón, Pilar
8Navio, Teresa
9Richi, Patricia
10Iagnocco, Annamaria
11Garrido, Jesús
12Martínez-Hernández, David
atitleAutomated radiofrequency-based US measurement of common carotid intima–media thickness in RA patients treated with synthetic synthetic and biologic DMARDs
jtitleRheumatology
risdate201302
volume52
issue2
spage376
epage381
pages376-381
issn1462-0324
eissn1462-0332
formatjournal
genrearticle
ristypeJOUR
abstractObjective. To compare the carotid intima–media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls. Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were recorded. Common carotid artery (CCA)-IMT was assessed in RA patients and controls with automated radiofrequency-based US by the same investigator at each centre. Forty-five (47.9%) RA patients had been treated with synthetic DMARDs and 49 (52.1%) with synthetic and biologic DMARDs. There were no significant differences between the RA patients and controls in demographics, CV co-morbidities and CV disease. There were significantly more smokers among RA patients treated with synthetic and biologic DMARDs ( = 0.036). Disease duration and duration of CS and synthetic DMARD therapy was significantly longer in RA patients treated with synthetic and biologic DMARDs ( < 0.0005). The mean CCA-IMT was significantly greater in RA patients treated only with synthetic DMARDs than in controls [591.4 (98.6) 562.1 (85.8); = 0.035] and in RA patients treated with synthetic and biologic DMARDs [591.4 (98.6) 558.8 (95.3); = 0.040). There was no significant difference between the mean CCA-IMT in RA patients treated with synthetic and biologic DMARDs and controls ( = 0.997). Our results suggest that radiofrequency-based measurement of CCA-IMT can discriminate between RA patients treated with synthetic DMARDs RA patients treated with synthetic and biologic DMARDs.
pubOxford University Press
doi10.1093/rheumatology/kes260
date2013-02